Glycomine
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
733 Industrial Rd, San Carlos, Californi...Phone Number
(650) 264-7560Website
www.glycomine.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Glycomine
Glycomine Inc., founded in 2014, is a private biotechnology company headquartered in San Carlos, California. The company focuses on developing replacement therapies for serious rare genetic disorders, particularly those involving metabolism and protein misfolding. Its lead candidate, GLM101, is a mannose-1-phosphate replacement therapy in clinical development for treating PMM2-CDG (CDG-1a), a congenital disorder of glycosylation. Glycomines approach combines substrates, enzymes, or proteins with targeted delivery systems to restore cellular function, aiming to address unmet medical needs in rare disease communities.Explore more
Glycomine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Glycomine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Glycomine has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Glycomine
Glycomine, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Glycomine recently announced quarterly report
Click to see if Glycomine had a recent Job posting/layoffs
Check out if Glycomine is spiking on competitors!
Funding: Get notified immidiatlly once Glycomine has new funding data
Product Launch: Get notified when Glycomine launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Glycomine as Masked Content
Find more new buyers
Compare Similar Companies to Glycomine
Compare insights from companies similar to Glycomine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Glycomine is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Glycomine is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Glycomine.
Glycomine financials insights
Gather financial insights about Glycomine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$33M
Glycomine Tech Stack
A closer look at the technologies used by Glycomine
Glycomine News & Media
Five Key Startups Shining the Light on Rare Diseases | Inside Precision Medicine
As investors flock to promising rare disease startups, check out our list of the top five investor favorites for their potential to bring new rare disease treatments to the market.Glycomine Appoints Joshua Grass as Chairperson of Board of Directors
SAN CARLOS, Calif.--(BUSINESS WIRE)-- #CDG--Glycomine Appoints Joshua Grass as Chairperson of Board of DirectorsGlycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDG
SAN CARLOS, Calif.--(BUSINESS WIRE)-- #CDG--Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLM101, a mannose-1-phosphate replacement therapy in development for the treatment of patients with phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG). “Fast Track Designation for GLM101 highlights its potential to meet the serious unmeGlycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG
SAN CARLOS, Calif.--(BUSINESS WIRE)-- #CDG--Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Glycomine
Sign Up For FreeTo access detailed company insights
Glycomine Inc., founded in 2014, is a private biotechnology company headquartered in San Carlos, California. The company focuses on developing replacement therapies for serious rare genetic disorders, particularly those involving metabolism and protein misfolding. Its lead candidate, GLM101, is a mannose-1-phosphate replacement therapy in clinical... Read More
